Disseminated cryptococcosis is a systemic fungal infection caused by encapsulated yeasts of the genus Cryptococcus, most often C. neoformans or C. gattii, and is distinguished from localized cutaneous forms by systemic rather than skin-confined involvement [1][2]. It may present with cutaneous manifestations as part of wider dissemination [2].
Disease overview
Fungal Evidence-backed information EN 5/7 applicable sections · ZH 5/7 applicable sections Updated Oct 23, 2026
Disseminated cryptococcosis is a potentially life-threatening fungal disease caused by encapsulated Cryptococcus yeasts, principally C. neoformans or C. gattii [1]. Cutaneous lesions may represent manifestations of disseminated disease rather than localized infection [2]. In public health terms, environmental exposure is difficult to avoid, though severe illness is preventable in advanced HIV populations through targeted antigen screening [3].
Read the full clinical and epidemiological profile 6
Cryptococcal meningitis is the most frequent human manifestation of cryptococcosis, and disseminated disease has been observed in previously healthy HIV-negative adults with neutralizing anti-GM-CSF autoantibodies [1]. Cutaneous involvement may indicate localized disease or disseminated/systemic cryptococcosis, a distinction clinicians consider more relevant than infection route [2]. The organism can persist undetected in weakened hosts, potentially progressing to life-threatening meningitis [3].
Localized cutaneous cryptococcosis is uncommon in Japan, with only 65 cases reported over a 50-year study period from 1968 to August 2018 [2]. Among these cases, 68% (n=44) occurred in immunocompromised patients and 32% (n=21) in immunocompetent patients, with none associated with human immunodeficiency virus (HIV) infection [2]. Consequently, localized cutaneous cryptococcosis affects both immunocompromised and well-appearing non-HIV-infected individuals, establishing its relevance in routine dermatology practice [2].
Cryptococcus is acquired from the environment and is difficult to avoid breathing in where it is present, though most exposed persons do not become ill [3].
No formal general recommendation exists to prevent cryptococcal infection because environmental exposure is hard to avoid [3]. For people with advanced HIV, targeted cryptococcal-antigen blood screening with antifungal treatment when antigen is detected can prevent severe or life-threatening disease [3]. Persons with possible cryptococcal symptoms should seek medical evaluation promptly [3].
- 1 Arango-Franco CA et al. Anti-GM-CSF Neutralizing Autoantibodies in Colombian Patients with Disseminated Cryptococcosis. J Clin Immunol. 2023 Jul. PMID: 36821021. doi: 10.1007/s10875-023-01451-5. PubMed: https://pubmed.ncbi.nlm.nih.gov/36821021/
- 2 Noguchi H et al. Cutaneous Cryptococcosis. Med Mycol J. 2019. PMID: 31787730. doi: 10.3314/mmj.19.008. PubMed: https://pubmed.ncbi.nlm.nih.gov/31787730/
- 3 US Centers for Disease Control and Prevention. Reducing Risk for Cryptococcosis | Cryptococcosis | CDC [Internet]. cited 23 Oct 2026. Available from: https://www.cdc.gov/cryptococcosis/prevention/index.html
Loading current data…
Country surveillance trends
Choose a country, source, and measure. Each line retains its published reporting period and definition.
Loading data…
Coverage
Reporting countries and regions
The map shows reporting coverage. Select a measure or open a shaded location to inspect its data.
Loading current data…
Surveillance pattern
Year × month seasonality by country
Review one country’s published monthly values by year. Empty cells indicate values the source did not publish.
Loading official alerts…
Downloads and methods
Choose a time range and download CSV, JSON or XLSX files.